Spectrofluorometric probe methods are developed and examined regarding their ability to model preferential solvation around probe molecules in binary solvents. The first method assumes that each fluorophore is solvated by only one type of solvent molecule and that each fluorophore contributes to the emission intensity. Expressions for this model are illustrated using fluorescence behavior of pyrene, benzo[e]pyrene, benzo[ghi]perylene, and coronene dissolved in binary n-heptane + 1,4-dioxane and n-heptane + tetrahydrofuran mixtures. The second method treats the solvational sphere as a binary solvent microsphere, with the fluorophore's energy in both the ground and the excited states mathematically expressed using the "nearly ideal binary solvent" (NIBS) model. Expressions derived from this model are illustrated using fluorescence behavior of 9,9'-bianthracene and 9,9*-bianthracene-10-carboxaldehyde in binary toluene + acetonitrile and dibutyl ether + acetonitrile.

Recent advancements in cancer research has led to the synthesis of a new drug known as docetaxel. Meant to replace paclitaxel, its more natural counterpart whose ingredients are difficult to obtain, the drug is known to effectively treat a wide array of cancers, including breast cancer, ovarian cancer, and prostate cancer. The establishment of a synthetic alternative to paclitaxel has increased its bioavailability, thereby lowering the cost needed to utilize the drug. Still, the limiting factor in minimizing costs is the method in which the drug is processed. Current methods in drug processing have their limitations, which include the introduction of impurities and a low effective yield due to poor powder geometry. Thus, the goal of this study looks to explore a new way to process the drug in a more efficient manner. In this study, a new method for processing docetaxel is explored on in great detail. A more direct method of using electrospray deposition is utilized for the creation of monodisperse nanoparticles, with the main intention of increasing the efficiency at which the drug is processed and prepared for drug delivery to the patient by means of injection. A key feature in electrospray deposition is its ability to produce droplets that are sized homogenously. These droplets eventually evaporate at homogenous rates. These two concepts have been exploited to consistently produce nanoparticles of the cancer drug, which is made possible by the fact that the minimal variation in droplet sizes has easily translated to minimal variation in dry particle sizes. Compared to other methods of drug processing, one other benefit that electrospray deposition conveys is that through evaporation, virtually all impurities and unwanted foreign material are eliminated.